wherein the substituents are described above, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts or

b) reacting a compound of formula



6

with a compound of formula



4

to a compound of formula



I

wherein the substituents are described herein, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

In another aspect, there is provided a compound as defined herein for use as therapeutically active substance.

In another aspect, there is provided a pharmaceutical composition comprising at least one of the compounds as defined herein, as well as its pharmaceutically acceptable salt.

In another aspect, there is provided a compound as defined herein, when applicable as mixtures of enantiomers, diastereomers, or in enantiomerically pure form; as well as its pharmaceutically acceptable salt, for use as a medicament.

~~In another aspect, there is provided use of a compound as defined herein, as well as its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prevention of diseases relating to allosteric modulators of $mGluR^5$ receptors.~~

In another aspect, there is provided a compound as defined herein for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.



I

wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

5. A compound according to any one of claims 1 to 3 for use as therapeutically active substance.

6. A pharmaceutical composition comprising at least one of the compounds according to any one of claims 1 to 3 as well as its pharmaceutically acceptable salt.

7. A compound of any one of claims 1 to 3, when applicable as mixtures of enantiomers, diastereomers, or in enantiomerically pure form; as well as its pharmaceutically acceptable salt, for use as a medicament.

~~8. The use of a compound according to any one of claims 1 to 3 as well as its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prevention of diseases relating to allosteric modulators of $mGluR^5$ receptors.~~

~~9~~8. A compound according to any one of claims 1 to 3 for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.